TDO2 and hepatocellular carcinoma: As shown in Figures 1(a) and 1(b), the expression of TDO2 was upregulated in most cancers, but it was downregulated in cholangiocarcinoma, hepatocellular carcinoma, and pancreatic adenocarcinoma (Figures 1(a) and 1(b)).